Tags : Coherus’

Insights+ Key Biosimilars Events of January 2020

Tuba Khan February 14, 2020

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Biosimilar is expanding its footprints worldwide with multiple collaborations. In Jan 2020, Pfizer launched its two biosimilars [Ruxience (biosimilar, rituximab) & Trazimera (biosimilar, trastuzumab)] at lowest WAC in the US Our team at PharmaShots has summarized key […]Read More

Insights+

Insights+: Key Deals Updates of JP Morgan Healthcare Conference 2020

Vartika Singh February 7, 2020

The 2020 JP Morgan Healthcare Conference was loaded with insights from key pharma companies. An analysis of events and catalysts that were announced or updated at the conference these days are included. Our PharmaShots team summarized the key deals which were presented during the updates from companies from Jan 13 to Jan 16, 2020. Date […]Read More

Weekly Snapshot

PharmaShots Weekly Snapshot (January 13-17, 2020)

Tuba Khan January 20, 2020

1. Arena’s APD418 Receives FDA’s Fast Track Designation to Treat Patients with Decompensated Heart Failure Published: Jan 17, 2020 | Tags: Arena, APD418, Receives, FDA, Fast Track Designation, Treat, Patients, Decompensated Heart 2. Charles River Collaborates with Fios Genomics for Bioinformatics-Driven Drug Discovery and Safety Assessment Published: Jan 16, 2020 | Tags: Charles River, Collaborates, Fios Genomics, […]Read More

Biosimilars

Coherus Signs a License Agreement with Innovent Biologics to Commercialize

Tuba Khan January 14, 2020

Shots: Innovent to receive $45M as upfront, development & regulatory milestone and royalties on sales of the therapy in the licensed territories while Coherus plans to file BLA to the US FDA in H2’20 or H1’21. Additionally, Coherus get an option to commercialize Innovent’s biosimilar to Rituxan (rituximab) in the US and Canada If option […]Read More

Biosimilars Insights+

Insights+ Key Biosimilars Events of November 2019

Vartika Singh December 6, 2019

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency. Biosimilars are expected to be a cost-effective alternative to high-priced branded biologics, offering significant and much-needed cost savings to both payers and patients. Hence physicians are likely to adopt biosimilars “a reference product to biologics” possessing similar […]Read More

Weekly Snapshot

PharmaShots Weekly Snapshot (November 04-08, 2019)

Tuba Khan November 11, 2019

1. Triumvira’s TAC01-CD19 Receives FDA’s Fast Track Designation for R/R Diffuse Large B-Cell Lymphoma Published: Nov 07, 2019 | Tags: Triumvira, TAC01-CD19, Receives, FDA, Fast Track Designation, R/R, Diffuse Large B-Cell Lymphoma 2. Janssen Reports Submission of MAA to EMA for its Investigational Ebola Vaccine Regimen to Prevent Ebola Virus Disease Published: Nov 07, 2019 | Tags: […]Read More

Biosimilars

Coherus Signs an Exclusive License Agreement with Bioeq for Biosimilar

Tuba Khan November 7, 2019

Shots: Bioeq to receive up front, regulatory and launch milestones with equal profit sharing. Coherus to get exclusive rights to commercialize biosimilar candidate referencing Genentech’s Lucentis with its anticipated launch in 2021 in the US Bioeq will be responsible for product delivery to the Coherus and will submit BLA to the US FDA in Q4’19 […]Read More

Biosimilars Regulatory

Coherus’ Udenyca (pegfilgrastim-cbqv) Receives the US FDA Approval for Patients

Vartika Singh November 5, 2018

Shots: Post EU Approval, Udenyca has received FDA approval on basis of non-inferiority data including its PK, PD and immunogenicity in 600 healthy patients, receiving myelosuppressive CT having cancer Udenyca novel pegfilgrastim-cbqv biosimilar, has received its EU approval on 21 Sep, 2018. In 2017, Pegfilgrastim had $4.5B sales worldwide Udenyca (formerly CHS-1701) is a PEGylated […]Read More

Amgen Collaborates with Evoq to Develop Novel Therapies for Autoimmune Disorders

Gilead Collaborates with VIR to Evaluate Combination Therapy for Chronic Hepatitis B Virus

Lilly and Merus Collaborate to Discover Novel T-Cell Re-Directing Bispecific Antibodies

Janssen Signs a Research Agreement with TenNor to Develop Treatments for Nontuberculous Mycobacteria Diseases

Innovent Out Licenses Byvasda’s (biosimilar, bevacizumab) Development and Commercialization Rights to PT Etana in Indonesia

Henlius’ HLX15 (biosimilar, daratumumab) Receives IND Approval for Multiple Myeloma in China

Celltrion Report Results of CT-P59 in P-II/III Study for COVID-19

The US Government to Purchase Additional Doses of Regeneron’s Casirivimab and Imdevimab to Combat COVID-19

Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) Receives EU’s Approval for the HER2 Positive Metastatic Breast Cancer

Omeros Reports the US FDA’s Acceptance and Priority Review of BLA for Narsoplimab (OMS721) to Treat HSCT-TMA

Sorrento Presents Preliminary Results of STI-2020 Against COVID-19

Biohaven’s Troriluzole Fails to Meet its Co-Primary Endpoints in P-II/III Study for Alzheimer’s Disease

Tags : Coherus’

Insights+ Key Biosimilars Events of January 2020

Insights+: Key Deals Updates of JP Morgan Healthcare Conference 2020

PharmaShots Weekly Snapshot (January 13-17, 2020)

Coherus Signs a License Agreement with Innovent Biologics to Commercialize

Insights+ Key Biosimilars Events of November 2019

PharmaShots Weekly Snapshot (November 04-08, 2019)

Coherus Signs an Exclusive License Agreement with Bioeq for Biosimilar

Coherus’ Udenyca (pegfilgrastim-cbqv) Receives the US FDA Approval for Patients

Latest Posts

Sorrento Presents Preliminary Results of STI-2020 Against COVID-19

Biohaven’s Troriluzole Fails to Meet its Co-Primary Endpoints in P-II/III Study for Alzheimer’s Disease

Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) Receives EU’s Approval for the HER2 Positive Metastatic Breast Cancer

Omeros Reports the US FDA’s Acceptance and Priority Review of BLA for Narsoplimab (OMS721) to Treat HSCT-TMA

Tags : Coherus’

Latest Posts

Categories

Related Topics